Saturday 17 October 2026 Export NNNN’s income statement to Excel — free account

Anbio Biotechnology

NNNN Healthcare Medical Instruments & Supplies

Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.

3.29 0.01 −0.30%

Follow NNNN

Alert me

Market cap: $474.8M
P/E: —
Fwd P/E: —
Dividend yield: —
F-score: 5/9
Altman Z: 8977.35
Beneish M: 2.00
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Dec '23	Dec '24	Jun '25	Dec '25
ROE Full definition →	+1 more TTM period Free account	—	—	—	0.00%
ROA Full definition →		—	—	—	0.00%
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		0.00%	0.00%	0.00%	0.00%
Average Days of Receivables Full definition →		0.00	0.00	0.00	0.00
Free Cash Flow per Share Full definition →		—	—	—	0.00
Free Cash Flow Full definition →		—	—	—	0.69
Capital Expenditures Full definition →		—	—	—	0.00
Other line items
Cash ROIC Full definition →		0.00%	0.00%	0.00%	1.64%
Average Days of Payables Full definition →		0.00	0.00	0.00	—
Operating CF/Net income Full definition →		—	—	—	0.00
Depreciation/Fixed assets Full definition →		—	—	—	0.00
Capex/Depreciation Full definition →		—	—	—	0.00
Operating CF per Share Full definition →		—	—	—	0.00
Capex per Share Full definition →		—	—	—	0.00
Capex to Sales Full definition →		—	—	—	0.00

Show all line items

Columns are period end dates